Because many chronic pain conditions remain difficult to treat with existing therapies, researchers have begun exploring the potential use of gene therapy in pain medicine. Disorders such as neuropathic pain, cancer pain, and inflammatory pain syndromes are commonly managed with opioids, anticonvulsants, antidepressants, and anti-inflammatory medications, but these treatments may provide incomplete relief and can produce significant adverse effects. Researchers have therefore investigated whether altering gene expression within the nervous system could eventually provide a more targeted approach to pain control (1). Although the field remains largely experimental, studies over the past two decades have explored how genetic techniques might influence pain signaling pathways. 

Most research on the use of gene therapy for pain medicine has focused on the peripheral nervous system, particularly sensory neurons located in the dorsal root ganglia. Investigators commonly use modified viral vectors, including herpes simplex virus (HSV), to deliver genes into nerve cells because HSV naturally infects sensory neurons (2). These vectors are engineered so they cannot cause infection but can transport selected genes into targeted tissues. In laboratory studies, researchers usually create animal models of chronic pain by producing nerve injury or inflammation and then evaluate whether gene transfer alters pain-related behaviors such as sensitivity to touch or heat. These studies are designed primarily to examine biological mechanisms rather than establish definitive clinical treatments. 

One major area of investigation involves genes associated with naturally occurring pain-modulating substances. Researchers have studied the preproenkephalin gene because it produces enkephalins, which are endogenous opioid peptides involved in reducing pain signaling within the nervous system (2). In some animal studies, HSV-mediated delivery of this gene was associated with reduced hypersensitivity after nerve injury. However, these findings remain preclinical and should be interpreted cautiously given the lack of human data. 

Inflammatory pathways have also been investigated as potential targets for pain-related gene therapy. Cytokines such as tumor necrosis factor-alpha and interleukin-1 beta are known to contribute to persistent sensitization of pain pathways in chronic inflammatory and neuropathic conditions (3). Experimental approaches have attempted to reduce the activity of these inflammatory mediators in animal models, with some studies reporting reductions in pain-related behaviors. Researchers have suggested that this strategy could eventually have relevance for conditions such as arthritis or diabetic neuropathy, although clinical evidence in humans remains limited. 

Human studies in this field are still rare. One of the best-known clinical investigations was a phase I trial conducted by Fink et al involving patients with severe cancer pain that was poorly controlled by conventional treatment (4). The study evaluated HSV-mediated delivery of the preproenkephalin gene and primarily focused on assessing safety. The investigators reported that the treatment was generally well tolerated, and some patients experienced reductions in pain scores. However, the study included a small number of participants and was not designed to establish long-term effectiveness. Additional large-scale clinical trials would be necessary before gene therapy could become a standard treatment option in pain medicine. 

Recent advances in molecular biology and gene-editing technologies have increased scientific interest in this field, but gene therapy for pain medicine remains investigational. Important challenges include ensuring long-term safety, controlling gene expression accurately, avoiding immune complications, and demonstrating clear clinical benefit in humans. At present, gene therapy should be viewed as a developing area of research rather than an established method of pain management. Continued research may clarify whether these experimental approaches can eventually contribute to future treatment strategies for chronic pain. 

References 

1. Ginn SL, Amaya AK, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):e3015. doi:10.1002/jgm.3015 

2. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther. 2009;17(1):13-18. doi:10.1038/mt.2008.213 

3. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10(1):23-36. doi:10.1038/nrn2533 

4. Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70(2):207-212. doi:10.1002/ana.22446